Issue Date: May 7, 2012
Resveratrol Rides Again
Ever since scientists learned about the red wine compound resveratrol’s reputed health and antiaging effects, they’ve been debating how the molecule works. The hubbub hinges on whether resveratrol targets sirtuin enzymes, the idea behind the biotech firm Sirtris Pharmaceuticals, which GlaxoSmithKline purchased for $720 million in 2008. The latest salvo comes from Harvard Medical School’s David A. Sinclair, a Sirtris founder, who for the first time . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society